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1. Introduction
The unpredictability of efficacy and toxicity of treatment are limitations of current standard
cancer treatments. The clinical results obtained by standard therapies suggest a need for a
paradigm change in cancer treatment. In recent years, immune cell therapy has been in the
spotlight with the expectation of opening the door to a new area of cancer therapy. Targeted
cancer therapy, which selectively takes action against targets expressed in the tumor surface,
seems to be promising.
The immune system can control various types of tumors. Antigen-non-specific innate immun‐
ity and antigen-specific adaptive immunity can reject tumors.
The identification of tumor antigens recognized by T cells has facilitated the development of
immune cell therapy in clinical oncology. The dendritic cell based cancer vaccine aims to
induce tumor specific effector T cells (cytotoxic T lymphocyte, CTL) that can reduce tumor
mass as well as tumor specific memory T cells that can control tumor relapse.
In this text, immune cell target therapy in clinical oncology will be discussed and hopefully
this will be helpful in daily clinical practice.
2. Role of natural killer cells
Natural killer (NK) cells are present in the peripheral blood and number approximately 10-15%
in the lymphocyte fraction. NK cells are the most important innate immune cell because of
their ability to directly kill target cells as well as produce immunoregulatory cytokines. NK
cells are defined by the surface expression of CD56, a neural cell adhesion molecule and lacks
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the T cell antigen CD3 [1]. The function of NK cells are direct cytotoxic activity against virus-
infected cells and tumor cells [2]. There are two distinct subsets of human NK cells based on
the density of surface CD56 expression [3]. Approximately 90% of human NK cells are CD
56dim and have high density expression of CD16, others are CD56bright and CD16dim/neg. The
CD56bright and CD56dim NK cell subsets show an important difference in cytotoxic potential,
capacity for cytokine production and response to cytokine activation (Table 1) [4].
CD56bright CD56dim
NK receptors
FcγRIII (CD16) -/+ + + +
KIR -/+ + + +
CD94/NKG2 + -/+
Cytokine receptors
IL-2Rαβγ + + -
IL-2Rβγ + + + +
CCR7 + + -
Adhesion molecules + + -/+
Effector functions
ADCC -/+ + + +
Natural cytotoxicity -/+ + + +
Cytokine production + + + -/+
*KIR indicated killer immunoglobulin-like receptor; IL, interleukin; ADCC, antibody-dependent cellular cytotoxicity.
Table 1. Functional Differences in Natural Killer (NK) cell Subsets* [2]
NK cells can mediate antibody-dependent cellular cytotoxicity (ADCC) through membrane
FcγRIII (CD16) expressed on the majority of NK cells. CD56dim NK cells are more cytotoxic
against NK-sensitive targets than CD56bright NK cells and respond to IL-2 with increased
cytotoxicity. It is of clinical importance to know that CD56 bright cells, after activation with IL-2,
can exhibit similar or enhanced cytotoxicity against NK targets compared with CD56dim cells
[5-7]. In addition, more than 95% of all CD56dim NK cells express CD16 (FcγRIII) and are capable
of ADCC. On the other hand, 50% to 70% of CD56bright NK cells lack expression of CD16 or
have only low-density expression of CD16 and therefore function minimally in ADCC.
It is well known that major histocompatibility complex (MHC) class I molecules are critical for
the inhibition of NK cell-mediated lysis of normal autologous cells [8, 9]. NK cells selectively
lyse autologous cell that have lost MHC class I self-expression [10].
In humans, two families of paired inhibitory and activating NK receptors have been identified,
killer immunoglobulin (Ig)-like receptor (KIR) family and the heterodimeric CD94/NKG2 C-
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type lectin family. In this text, these receptors are not discussed in order to simplify the clinical
application of NK cell therapy. Although the activating KIR and CD95/NKG2 receptors are
important in mediating NK cytotoxicity, Natural Cytotoxicity Receptors (NCR) and the
homodimeric NKG 2D receptors may be important in mediating cytotoxicity against abnormal,
MHC class I-deficient, or class I-negative targets. This biological information will result in the
clinical application of NK cell-based therapies for cancer. Table 2 shows the incidence of MHC
class I deficient or negative cancer cells.
Tumor cell Incidence (%)
Uterine cervical cancer 90
Osteosarcoma
Primary 52
Metastatic 88
Breast cancer 81
Pancreatic cancer 76
Prostate cancer 74
Colon cancer
Primary 32
Metastatic 72
Sarcoma 62
Melanoma
Primary 16
Metastatic 58
Head and neck cancer 49
Hepatoma 42
Renal cell carcinoma 38
Lung cancer 38
Ovarian cancer 37
Pharyngeal cancer 56
Urinary bladder cancer 25
Table 2. Incidence of MHC class I deficient or negative cancer cells [11]
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It is presumed that the difference of MHC class I expression may be the difference in the
clinical efficacy of NK cell based immune therapy. Because of the variety of cancer cells,
it is not enough to kill all cancer cells by NK cell-based therapy. It is necessary to target
a cancer specific antigen by cytotoxic T cells, which are activated by a Dendritic Cell (DC)-
based cancer vaccine (Figure 1).
Figure 1. Cytotoxicity of NK cells [11]
3. Strategies using dendritic cell vaccine
Dendritic cells (DCs) are key regulators of both T- and B-cell immunity, because of their
superior ability to take up, process and present antigens compared with other antigen
presenting cells (APCs) [12]. DCs can also activate NK cells and natural killer T (NKT) cells
[13]. Because of these functions, DCs can conduct all of the elements of the immune orchestra
and they are therefore a fundamental target and tool for vaccines [14]. Cancer related antigens
are a key factor implicated in the design of DC vaccine strategies. If a patient’s own cancer cells
are available for lysate, this will be used for the production of an individual DC-based vaccine,
which is utilized for the optimally matched tumor surface antigen. In most instances, however,
if a patient’s own cancer cells are not available, then artificial cancer antigens are utilized for
the production of a DC-based cancer vaccine.
A pilot project by the National Cancer Institute reported on the prioritization of cancer antigens
to develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on
predefined and preweighted objective criteria [15]. Antigen prioritization involves developing
a list of ideal cancer antigen criteria (Figure 2).
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Figure 2. Cancer antigen pilot prioritization: representation of ranking based on predefined and preweighted criteria
and subcriteria. Inset, the color used to designate each criterion and its relative weight. Number at the end of each
bar, relative rank of that antigen. [15]
Among these, frequently used artificial tumor antigens are listed below. Some of these are
restricted by HLA-A1 or HLA-A24, so that an HLA study is needed to select and match the
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tumor antigens to the DCs (Table 3). Certain artificial tumor antigens cannot apply depending
on HLA types on DCs and tumor cells.
HLA-A2 or HLA-A24 restricted Non-restricted
WT1
CEA
MAGE-1, MAGE-3
HER 2
gp100
NY-ESO-1
PSMA
SART-1, SART-3
MART-1
Melan-A
HPV16-E7
MUC1
CA125
PSA
NY-ESO-2
Table 3. Typical artificial tumor antigens.
WT1 peptide is a part of long chain of WT1 protein (Figure 3).
 10 20 30 40 50 
MGSDVRDLNA LLPAVPSLGG GGGCALPVSG AAQWAPVLDF APPGASAYGS 
60 70 80 90 100 
LGGPAPPPAP PPPPPPPPHS FIKQEPSWGG AEPHEEQCLS AFTVHFSGQF 
110 120 130 140 150 
TGTAGACRYG PFGPPPPSQA SSGQARMFPN APYLPSCLES QPAIRNQGYS 
160 170 180 190 200 
TVTFDGTPSY GHTPSHHAAQ FPNHSFKHED PMGQQGSLGE QQYSVPPPVY 
210 220 230 240 250 
GCHTPTDSCT GSQALLLRTP YSSDNLYQMT SQLECYTWNQ MNLGATLKGV 
260 270 280 290  
AAGSSSSVKW TEGQSNHSTG YESDNHTTPI LCGAQYRIHT HGVFRGIQDV 
310 320 330 340 350 
RRVPGVAPTL VRSASETSEK RPFMCAYPGC NKRYFKLSHL QMHSRKHTGE 
360 370 380 390 400 
KPYQCDFKDC ERRFSRSDQL KRHQRRHTGV KPFQCKTCQR KFSRSDHLKT 
410 420 430 440 449 
HTRTHTGKTS EKPFSCRWPS CQKKFARSDE LVRHHNMHQR NMTKLQLAL 
 
Figure 3. Amino acid sequence of WT1 protein (Total length 449, mass (Da) 49,188)
Cancer Treatment - Conventional and Innovative Approaches304
Wild sequence: RMFPNAPYL (126-135), HLA-A2 restricted
Modified sequence: CYTWNOMNL (235-243), HLA-A24 restricted
The sequence RMFPNAPYL is called wild type and is HLA-A2 restricted. Another sequence
CYTWNQMNL is a modified type and is HLA-A24 restricted. WT1 is expressed on the cell
surface of carcinomas such as esophageal, gastric, colorectal, pancreas, biliary tract, liver,
breast, uterus, brain, lung (non-small cell), malignant melanoma, sarcoma, acute myeloid and
lymphoid leukemia, salivary gland and prostate, etc.
Another important tumor antigen to be targeted is MUC1 which is the cell membrane associ‐
ated protein. The sequence of this peptide is TRPAPGSTAPPAHGVTSAPDTRPAPGSTAP and
is HLA-non restricted (Figure 4). MUC1 is presented over the surface of cancer cells of the
esophagus, stomach, colorectal, pancreas, biliary tract, breast, uterus, ovary, salivary gland,
lung (adenocarcinoma), prostate and so on.
Figure 4. Sequence of MUC1 peptide.
Recently, new therapy strategies that focus on tumor associated antigens (TAAs) have been
suggested as additional options to currently available treatments, due to their fewer adverse
events and better tolerability. The establishment and maintenance of immune cell therapy for
cancer relies on special TAAs, such as WT1 and MUC1 which have become primary targets
for cancer vaccines [16, 17].
The high risk of metastatic recurrence suggests that cancer cell dissemination may occur early
in most carcinomas, and therefore it seems that active immunotherapy may have a place among
treatment modalities [18]. Among TAAs, above mentioned WT1 and MUC1 have received
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particular attention as potential targets for vaccine-based immunotherapy, because with the
exception of very few tissues such as the splenic capsule and stroma, they are not expressed
in normal human tissues and become activated in a number of cancers [19-21]. Therefore
vaccination is an effective medical procedure in clinical oncology, based on the induction of a
long-lasting immunologic memory and characterized by mechanisms endowed with high
destructive potential and specificity. These functions will elicit a persistent immune memory
that can eliminate residual cancer cells and protect against relapses.
On this basis, vaccination strategies employing DCs have been regarded as a promising
therapeutic approach, even for advanced cancer. DCs internalize the cancer antigen, process
their protein and then displays them, as short peptides on their extra cellular surface in
conjunction with major histocompatibility complex (MHC) class I and II molecules. DCs then
migrate into corresponding lymph nodes, where they mature and present the antigen to naïve
T lymphocytes. Helper T cells (CD4+) recognize their cognate antigens (MHC class II molecules)
on DCs, where CD8+ cytotoxic T lymphocytes (CTLs) recognize foreign or cancer cells that
display the complementary peptide-MHC class I molecule on their cell surface. Adapting
single peptides for the development of vaccines is not an optimal approach. It has been shown
that after a complete objective response to the NY-ESO-1 peptide vaccine, a NY-SEO-1 negative
tumor later recurred, showing that single-target immunization approaches can result in the
development of immune escape tumor variants [22]. Since MHC expression levels vary with
tumor types and stages, it is difficult to eradicate cancer by administration of NK cells alone.
So, it is rational to use NK cell together with cancer vaccine, which we call hybrid immune
therapy. CTLs activated by DC-based vaccine target MHC expressing cancer cells, where NK
cells attack cancers that do not express MHC. We have proposed WT1, MUC1, CEA, CA125
and HER2/neu as potential cancer antigens for DC-based cancer vaccine, according to the
patient’s primary lesions and the tumor markers [23-26]. It has been reported that WT1 and
MUC1 are antigens with high immunogenicity and their targeted immunotherapy has
confirmed their safety and clinical efficiency. However, there are few studies regarding cancer
vaccines that simultaneously use WT1 and MUC1 as antigens [27].
Preparations of DCs are as follows; PBMC-rich fraction is obtained usually by leukapheresis
using COM. TEC (Fresenius Kabi, Hamburg, Germany). PBMCs were isolated from the
heparinized leukapheresis products by Fi-coll-Hypaque gradient density centrifugation [28].
These PBMCs are placed into 100mm plastic tissue culture plates (Becton Dickinson Labware,
Franklin Lakes, NJ) in AIM-V medium (Gibco, Gaithersburg, MD). Following 30 min incuba‐
tion at 37deg C, non-adherent cells are removed and adherent cells were cultured in AIM-V
medium containing granulocyte-macrophage colony stimulating factor (GM-CSF, 500ng/ml,
Primmune Inc., Kobe, Japan) and IL-4 (250ng/ml, R&D Systems Inc., Minneapolis, MN), to
generate immature DCs [29]. The population of adherent cells remaining in the wells is
composed of 95.6 +/- 3.3% CD14+ cells. After 5 days of cultures, the immature DCs are stimu‐
lated with OK-432 (10μ/mL) and prostaglandin E2 (50ng/mL, Daiichi Fine Chemical Co., Ltd.,
Toyama, Japan) for 24 hours to induce differentiation. Then, WT1, MUC1 and other antigens
or proteins are pulsed onto the DCs in the same culture media are incubated for 24 hours. The
concentrations usually used are shown (Table 4).
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WT1 20μg/mL
MUC1, long peptide (30-mer) 20μg/mL
CEA peptides 20μg/mL
CA125 protein 500μg/mL
HER2 20μg/mL
Autologous tumor lysates 50μg/mL
Table 4. Concentrations of peptide using DC vaccine
To prepare the autologous tumor lysates, tumor masses were obtained by surgical resection
exclusion and are homogenized. Aliquots of isolated tumor cells were then lysed by 10 cycles
of repeated freeze in liquid nitrogen and thaw in a 37deg C water bath. The lysed cells were
centrifuged at 14,000G for 5 min, and supernatants are passed through a 0.22μm filter
(Millipore Corporation, Bedford, MA). Protein concentrations in the resultant cell-free lysates
are determined using DC protein assay kits (Bio-Rad Laboratories, Hercules, CA). Aliquots
(500μg/tube) are then cryopreserved at -135deg C until use [30]. Surface molecules are
determined using flow cytometry. The cells defined as mature DCs are CD14-, HLA-DR+, HLA-
ABC+, CD83+, CD86+, CD40+ and CCR7+. Vaccine quality control and FACS analysis are as
follow; All vaccines are subjected to quality control evaluation, which involves assessing the
total number of live DCs, monocyte-derived DC characteristics and percentage of viable cells.
For vaccine to be deemed “adequate” 4x107 viable DCs are required. The frozen DC cells are
allowed to thaw quickly in a 37deg C water bath and are retrieved from the cryopreservation
tube by rinsing with 0.02% albumin-containing FACS buffer cell WashTM (Bioscience, San Hose,
CA). The FACS analysis is performed for cell surface antigen detection. FITC-labeled anti-
human CD14, CD40, CD80, HLA-A, B, C, PE-labeled anti-human CD11C, CD83, CD197
(CCR7+), HLA-DR and the FACS Calibur flow cytometer were used from DC Biosciences
(Franklin Lakes, NJ).
4. Role of hyperthermia in DC vaccine therapy
Hyperthermia is widely used to enhance the efficiency of chemotherapy or radiation in patients
with inoperable cancer [31]. It has been given much attention for the cellular response to heat
stress with respect to the immune system in cancer. The anti-tumor immune response can be
markedly enhanced by treatment with hyperthermia particularly in the fever range [32].
Immunological effects of mild hyperthermia are twofold. One is the effect on dendritic and
other immune cells [33]. The other is the effect is on tumor cells. Protein or peptides derived
from cancer which are chaperoned by heat-shock protein (HSP) are possible sources of
antigens, transferred to antigen presenting cells for priming CD8+ T cell responses [34]. Human
tumor-derived HSP70 peptide complexes (HSP70-PC) have the immunogenic potential to
instruct DCs and cross-present endogenously expressed, nonmutated, tumor antigenic
peptides. The cross-presentation of a shared human tumor Ag together with its exquisite
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efficacy is an important new aspect for HSP70-based immunotherapy in clinical anticancer
vaccination strategies, and suggest a potential extension of HSP70-based vaccination protocols
from a patient-individual treatment modality to its use in an allogeneic setting [35]. The other
studies support various clinical use of hyperthermia as part of an immunotherapeutic strategy
in treating cancer [32, 36].
The mechanisms by which a tumor cell can escape CTL is critical for the design and modifi‐
cation of effective vaccine strategies against cancer. These mechanisms fall into four broad
categories: (i) inadequate antigen presentation by tumor cells resulting in their poor sensitivity
to lysis by CTL; (ii) inhibitory signals provided by the tumor microenvironment; (iii) inability
of TAA-specific CTL to localize at a tumor site; and (iv) inability of the tumor microenviron‐
ment to sustain T cell function in vivo [37]. Therefore, adequate antigen expression by tumor
cells is of crucial importance. Many research papers show the possible augmentation of MHC
class I antigen presentation via heat shock protein expression by hyperthermia. It has been
demonstrated that the cell surface presentation of MHC class I antigen is increased in tandem
with increased heat shock protein 70 (HSP 70) [38]. It is clear that mild hyperthermia enhances
both the expression of TAA on the surface of tumors and also increased presentation of TAA
chaperoned by HSP on the dendritic cell. These findings are encouraging for usage of hyper‐
thermia at the time of DC vaccination.
5. Clinical results in miscellaneous cancers
Indications for the DC-based cancer vaccine is summarized as follows:
1. Patients with advanced cancer refractory to standard treatments.
2. Cancer patients treated with standard treatments without satisfactory results.
3. Efficiency of current standard therapy is not expected, but there are some possibilities to
improve quality of life and prolong survival time by use of DC-based vaccine.
Prevention of relapse or metastasis after surgery or other standard treatments.
In this communication, the results of the retrospective study of the DC-based vaccine are
presented in cancers common in Japan. Most of these patients are called “cancer refugees” who
are told that no further effective treatments are available. Patient evaluations included a
medical history and physical examination which include measurement of performance status
(PS), total protein, albumin, hemoglobin, WBC count, platelet count, blood urea nitrogen
(BUN), creatinine, alkaline phosphatase, LDH, AST, ALT, bilirubin, HbA1c, tumor marker
level and HLA. As an image marker, computed tomography (CT) scans or magnetic resonance
image (MRI) as well as ultrasound studies were included. To be eligible, patients were required
to have an ECOG PS of <3. They were also required to have adequate hematologic and
hepatorenal functions as determined by the flowing parameters:
WBC counts of≧2,500/μL, platelet counts of≥80,000/μL, hemoglobin value of≧9.0g/dL,
BUN<50mg/dL, serum bilirubin level <5.0mg/dL and AST level<50DIU/L.
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Autologous DCs (1x107 cells) were administered intradermally at 14-day intervals, for a total
of 6-8 times. Tolerable 1 to 5 KE doses of OK-432 (Chugai Pharmaceutical Co., Ltd., Tokyo, a
streptococcus immunological adjuvant) was administered together with the DC vaccine. NK
cells were simultaneously injected intravenously in some patients at 14-day intervals. Clinical
response was evaluated according to the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.0 as follows: complete remission (CR), partial remission (PR), stable disease
(SD) and progressive disease (PD). Adverse events were evaluated by grading the toxicity
according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0. The most common advanced cancers that were refractory to
standard treatments that were treated by our DC-based cancer vaccine were as follows: breast
cancer, lung cancer, pancreatic cancer, and colorectal cancer (Figures 5-8). The most important
factor for prolonged survival was good PS before entry into DC vaccine treatment. Patients in
the better PS group had a significantly longer survival time compared to those in the poorer
group. The overall survival (OS) based on our risk score was significantly better for patients
with clinical response of CR, PR and SD compared to those with a response of PD group.
Therapy was well tolerated during treatment and for 3 months after the final treatment. None
of the patients experienced adverse events of grade 3 or higher during the treatment period.
Grade 1 to 2 fevers and grade 1 injection site reactions, consisting of erythema, induration and
tenderness lasting 1-5 days after injection occurred in most patients and did not result in any
dosage modifications or delayed treatments. No signs of autoimmune disease (arthritis, rash,
colitis, etc.) were observed either during or after therapy.
 
Figure 5. Clinical response of DC vaccine in advanced breast cancer refractory to standard treatment.
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 Figure 6. Clinical response of DC vaccine in advanced lung cancer refractory to standard treatment.
 
Figure 7. Clinical response of DC vaccine in advanced colorectal cancer refractory to standard treatment.
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 Figure 8. Clinical response of DC vaccine in advanced pancreatic cancer refractory to standard treatment.
The current results show that the DC-based vaccine is clinically applicable to any patient with
a good PS at the initiation of DC-based therapy and can clinically benefit from continuing
therapy beyond disease progression. Of the professional APCs, DCs are the most potent
stimulators of T cell responses and play a crucial role in the initiation of primary immune
responses [12]. Despite several immunotherapeutic approaches tested in colon cancer patients,
only one has reported clinical results in a prospective randomized trial [39]. Preclinical data
suggest that DC-based vaccines exert cytotoxic actions and that prolonged vaccine exposure
is necessary for continued cancer suppression [40]. However, precisely when the full efficacy
of antitumor vaccines will be realized, and when this approach will become routine therapy
is difficult to predict. To date, most of peptide-based vaccines have targeted HLA class I-
restricted peptides. However, there is increasing evidence that tumor-specific CD4+ T cells may
also be important in inducing effective antitumor immunity. An ideal TAA is a protein that is
essential for sustaining the malignant phenotype but which is not removed or down-regulated
by the immune reaction. TAAs have been categorized according to their characteristics, such
as therapeutic function, immunogenicity, oncogenicity, specificity, expression level, number
of positive cells, and cancer stem cell expression.
It is important to understand the immunological mechanisms underlying the significant
increase in cancer control ratios. Our results indicate that WT1 and /or MUC1-pulsed DC-based
vaccination can have significant clinical benefits, even for advanced cancer patients that are
refractory to standard therapies. These encouraging preliminary results suggest that WT1-
and/or MUC1-pulsed DC-based vaccination strategies warrant further study as novel thera‐
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peutic approaches to patients with advanced carcinomas. The combination of cytotoxic
therapy with immune stimulation against cancer has been studied preclinically for a variety
of common tumor types and could be directly translated to clinical use [41-43]. The current
result clearly supports the idea that quality specifications are of the highest priority and must
be important considerations in any future vaccine-based study.
Moreover, the induction of memory T and B cells underlies immunological memory induced
by vaccination [44]. The ability of memory T cells to confer protective immunity depends on
the number and quality of the cells produced [45, 46]. In the current study patients with an
outcome of SD lived for a relatively long time, which is unusual for other therapeutic modal‐
ities. This tendency may due to CTL proliferation and differentiation into effector memory
CD8 cells.
Given the wide interest for vaccine intervention in treating miscellaneous cancers, our findings
may help in guiding and designing future trials. Additional studies are necessary to identify
appropriate targets for vaccine development in this new era of molecular-targeted agents for
cancer treatment.
6. Discussion and conclusion
A better understanding of cancer molecular biology would enhance the design of novel
therapies for cancer. Currently the scope of cancer immunotherapy is limited because most
targeted antigens are restricted to a subset of patients. Molecular target DC vaccines evoke the
power of each patient’s immune system to help prevent recurrence and increase the long-term
survival rate. If the patient’s resected tumor is available, lysate is used as molecular antigens.
Using this lysate, the vaccine induces an immune response against cancerous cells and creates
immunologic memory. Because it is derived from the individual patient’s tumor cells, this
vaccine is a true targeted and personalized cancer therapy. When patient’s own tumor cells
are not available, integrating several candidates of peptides such as WT1, MUC1, CEA, CA125,
Her2, PSA etc. can be used for the design of an anti-tumor vaccine which are restricted to the
patient’s HLA typing. Among these antigens, it is known that WT1 and MUC1 are the most
important antigens expressed in cancer stem cells. Cancer stem cells form new tumors and
may not be eliminated by chemotherapy or radiation. This has changed the perspective with
regard to new approaches for treating cancer. Cancer stem cells are slow-dividing and
inherently chemotherapy resistant. Eradication of these cancer stem cells may be necessary for
the long-term success in cancer treatment. Using this strategy, a DC vaccine pulsed with WT1
and MUC1 and other tumor specific antigens would be used to eliminate cancer stem cells in
individual patients. Hyperthermia is often used to activate immune system. There is evidence
that when DCs take up HSPs together with the peptide they chaperone, the accompanying
peptides are delivered into the antigen-processing pathways, leading to peptide presentation
by MHC molecules. When DCs travel to the lymph nodes, T cells recognize the antigenic
peptides and are specifically activated against cancer cells bearing these peptides [47]. Finally,
the clinical results of molecular target cell therapy for cancers involving different organs, using
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the DC vaccine and or combination with natural killer cells are discussed. The response rate
and cancer control rate of advanced breast cancer, lung cancer, colorectal cancer and pancreatic
cancer are 12% and 38%, 22.7% and 68.2%, 21.9% and 59.4%, 16.9% and 42.9%, respectively.
Overall survival rates were more than that of expected in advanced cancer refractory to
standard therapy. These findings of DC based vaccines suggest the usefulness for treating
cancer patients. Given the wide interest for targeted vaccine intervention in treating miscella‐
neous cancers, our findings may help in guiding and designing future trials and the develop‐
ment of novel cancer treatment strategies.
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